Trials / Completed
CompletedNCT01887275
A Control Study to Evaluate The Efficacy And Safety of Ozone-therapy in Chronic Hepatitis B
Medical Ozone Versus Conventional Interferon-α Treatment of Patients With Chronic Hepatitis B -A Control Study to Evaluate The Efficacy And Safety of Ozone-therapy in Chronic Hepatitis B
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 439 (actual)
- Sponsor
- Nanfang Hospital, Southern Medical University · Academic / Other
- Sex
- All
- Age
- 12 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to investigate the efficacy and safety of medical ozone in treatment of chronic hepatitis B patients.
Detailed description
Total of 439 patients with chronic hepatitis B were divided according to patients' intention into two arms. 173 patients in arm I were treated with medical ozone therapy with humares which was made in Germany for at least 12 weeks.266 patients in arm II were treated with conventional interferon-α for at least 24 weeks.Patients in both groups were followed-up for 24 weeks.Virology response, biochemistry response and hepatitis B viral serological response will be studied at 12 weeks after the treatment, at the end of treatment and after 24 weeks of follow-up.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | medical ozone therapy with humares | Medical ozone therapy with instrument made in Germany Patients in this group will receive autohemotherapy treatment. First month: ozone concentration: 20µg \~40µg /ml;The second month: 30µg/ml × 100ml oxygen- ozone gas × 100 ml blood;The third month: 20µg/ml × 100ml oxygen- ozone gas× 100 ml blood. |
| DRUG | conventional interferon-α | Patients in the conventional interferon-α treatment group received subcutaneouslly injection of 5 million units of conventional interferon-α in three times per week for at least 24 weeks. |
Timeline
- Start date
- 2010-03-01
- Primary completion
- 2013-02-01
- Completion
- 2013-02-01
- First posted
- 2013-06-26
- Last updated
- 2013-06-26
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT01887275. Inclusion in this directory is not an endorsement.